PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex™ (clevidipine butyrate) injectable emulsion, were published in the August issue of the Annals of Emergency Medicine. The clinical trial demonstrated that Cleviprex is safe and effective for the treatment of acute, severe hypertension. Cleviprex was approved this month by the U.S. Food and Drug Administration (FDA) for the reduction of blood pressure when the use of oral therapy is not feasible or not desirable.
